Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
about
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.Non-infectious pulmonary toxicity of rituximab: a systematic review.Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritisInterleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study.TNFalpha blockade in human diseases: an overview of efficacy and safety.Protective effect of an extract from Ascaris suum in experimental arthritis models.The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.Abatacept: a novel treatment for rheumatoid arthritis.Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.Investigation of latent tuberculosis infection in patients with psoriasis who are candidate for receiving immunobiological drugs.Steroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies.Protein biochip array technology to monitor rituximab in rheumatoid arthritis.
P2860
Q33387149-934973B3-33BE-4CCF-A83E-7519FC7CD2A5Q33529391-1244D90C-7C42-4CB8-97BC-289CFA8C3F2EQ33554356-8F366B39-EC15-478A-8F66-51F85BBF1D9BQ33944344-39C490CB-EA95-46FE-BFB8-5ECE7113A755Q34096300-51660193-7B0A-4C07-9822-2F547B597CAAQ35954640-4EB6798E-65A4-46AB-9C04-8EAF5DD21413Q36160421-4FD059D8-973E-44D4-A64A-F6938F39D9C7Q36392408-BE7112CC-B304-4951-8439-355A1A18364BQ36536861-3529ABFA-C731-46DC-B8AD-28BE55CA2B98Q36710601-05FA7517-72D9-42C2-A7EE-49BA1D5D90D8Q36790391-0CA20FB4-3F69-4342-8FEA-154B79C63289Q36847326-D1DABA21-0593-4239-AAC8-2C12808C8117Q36916918-05F6755F-692F-402E-9F7E-0FC5E0D00F33Q36934649-F468A897-E21D-4715-B87A-229B0B877096Q36967284-4763EB9B-4694-4683-A747-4F68F500C096Q37106639-618335FD-4C78-4522-8740-31A1BB4A9A25Q37210207-47CEC04D-E45D-4D6D-8F90-7A5E299425B5Q37517575-83EAEE7E-AF7D-4A45-AB51-D150C8B251CBQ37944171-81EE18D5-F774-4AC4-9854-B1A29D382598Q38270024-60CDBC64-8F4D-40BB-A148-E82F47298480Q40002229-BBE036C2-D6A9-48BC-A61B-D10A5776E836
P2860
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@ast
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@en
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@en-gb
type
label
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@ast
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@en
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@en-gb
prefLabel
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@ast
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@en
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@en-gb
P2093
P2860
P356
P1476
Updated consensus statement on ...... t of rheumatic diseases, 2006.
@en
P2093
E C Keystone
F C Breedveld
J R Kalden
J S Smolen
M E Weinblatt
M H Schiff
M H Weisman
P L C M van Riel
P2860
P304
P356
10.1136/ARD.2006.061937
P407
P478
65 Suppl 3
P577
2006-11-01T00:00:00Z